Search - tctmd.com

Displaying 1 - 20 of 94

Sort: Relevancy | Date

News Daily News

European Guidelines Represent First Intersocietal Position on Percutaneous PFO Closure

Yael L. Maxwell

November 01, 2018

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

Caitlin E. Cox

October 04, 2018

Presentation TCT 2018

LAA Closure: Challenging Case Vignettes

Presenter: Saibal Kar, Horst Sievert, Philippe Garot, Jan Kovac, Ashish Pershad, Ramon Quesada, Peter B. Sick, Brian K. Whisenant

September 24, 2018

Presentation TCT 2018

The Big Picture: Choosing the Right Device for the Right Anatomy

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

Epicardial LAA closure: From Surgical Results to Transpericardial Applications

Presenter: Saibal Kar, Horst Sievert, Krzysztof Bartus

September 24, 2018

Presentation TCT 2018

SeaLA: Differentiating Features, Technique and Outcomes

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

Cardia: Differentiating Features, Technique and Outcomes

Presenter: Saibal Kar, Horst Sievert, Reda Ibrahim

September 24, 2018

Presentation TCT 2018

Optimal Technique and Tips for Amulet Implantation

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

Optimal Technique and Tips for Watchman Implantation

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

The Watch TAVR Trial: Rationale, Design and Status

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Samir R. Kapadia

September 24, 2018

Presentation TCT 2018

The WaveCrest Device and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Gregg W. Stone

September 24, 2018

Presentation TCT 2018

The Amulet Platform, Experience and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Apostolos Tzikas

September 24, 2018

Presentation TCT 2018

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

Presenter: Vivek Y. Reddy, Brian K. Whisenant

September 24, 2018

Presentation TCT 2018

FDA Perspectives on New Devices and Indications for LAA Closure

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Andrew Farb

September 24, 2018

Presentation TCT 2018

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Paul D. Varosy

September 24, 2018

Presentation TCT 2018

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Presenter: James B. Hermiller Jr, David Hildick-Smith, George S. Hanzel

September 24, 2018

Presentation TCT 2018

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Presenter: James B. Hermiller Jr, David Hildick-Smith, Martin W. Bergmann

September 24, 2018

Presentation TCT 2018

Essential of Pre-procedural Imaging and Intra-procedural Guidance

Presenter: James B. Hermiller Jr, David Hildick-Smith, Jacqueline Saw

September 24, 2018

Presentation TCT 2018

Shared Decision-making in NVAF: The Patients Perspective

Presenter: James B. Hermiller Jr, David Hildick-Smith, Megan Coylewright

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Advertisement

European Guidelines Represent First Intersocietal Position on Percutaneous PFO Closure

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

LAA Closure: Challenging Case Vignettes

The Big Picture: Choosing the Right Device for the Right Anatomy

Epicardial LAA closure: From Surgical Results to Transpericardial Applications

SeaLA: Differentiating Features, Technique and Outcomes

Cardia: Differentiating Features, Technique and Outcomes

Optimal Technique and Tips for Amulet Implantation

Optimal Technique and Tips for Watchman Implantation

The Watch TAVR Trial: Rationale, Design and Status

The WaveCrest Device and US Pivotal Trial

The Amulet Platform, Experience and US Pivotal Trial

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

FDA Perspectives on New Devices and Indications for LAA Closure

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Essential of Pre-procedural Imaging and Intra-procedural Guidance

Shared Decision-making in NVAF: The Patients Perspective

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content